Clinically significant incidental QTc prolongation is subject to within-individual variability.


Journal

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc
ISSN: 1542-474X
Titre abrégé: Ann Noninvasive Electrocardiol
Pays: United States
ID NLM: 9607443

Informations de publication

Date de publication:
03 2020
Historique:
received: 16 05 2019
revised: 15 07 2019
accepted: 04 08 2019
pubmed: 10 9 2019
medline: 2 3 2021
entrez: 10 9 2019
Statut: ppublish

Résumé

Prolonged QTc interval observed in daily practice is often deemed to be drug induced and might result in drug discontinuation, with possible therapeutic consequences. However, whether clinically significant prolonged QTc may be due to within-individual variability occurs has yet to be described. A retrospective cohort study documenting within-individual QTc variability in subjects attending annual routine medical evaluation. At each visit, QT interval was measured and corrected for heart rate using Bazett and three other commonly used formulae. Outcome measures were rates of ΔQTc ≥60 msec, absolute QTc ≥500 msec and QTc ≥25% from baseline. A total of 188 subjects [54 (29%)] females were recruited. Mean age at first ECG was 54 ± 12.8 years with mean time interval of 12.2 ± 1.1 months between measurements. Mean Bazett QTc was higher compared to the other 3 formulae: 412 ± 20 vs. 400 ± 16 msec. Using Bazett formula, 18/188 (9.6%) and 5/188 (2.7%) subjects showed at least one measurement with ΔQTc ≥60 msec and QTc ≥500 msec, respectively. Of the former, 5/18 (27.8%) showed QTc ≥25% prolongation. In multivariate analysis, QTc ≥500 msec was significantly associated with number of measurements (HR: 5.01, 95%CI: 1.21-20.78, p = .026) with no effect of other known confounders. Lower rates were demonstrated with the other three formulae. In clinical practice, significant prolonged QTc may be attributed to within-individual variability, particularly when adjusting the QT interval with Bazett correction. This should be taken into consideration when decisions on changing current drug regimens are to be made.

Sections du résumé

BACKGROUND
Prolonged QTc interval observed in daily practice is often deemed to be drug induced and might result in drug discontinuation, with possible therapeutic consequences. However, whether clinically significant prolonged QTc may be due to within-individual variability occurs has yet to be described.
METHODS
A retrospective cohort study documenting within-individual QTc variability in subjects attending annual routine medical evaluation. At each visit, QT interval was measured and corrected for heart rate using Bazett and three other commonly used formulae. Outcome measures were rates of ΔQTc ≥60 msec, absolute QTc ≥500 msec and QTc ≥25% from baseline.
RESULTS
A total of 188 subjects [54 (29%)] females were recruited. Mean age at first ECG was 54 ± 12.8 years with mean time interval of 12.2 ± 1.1 months between measurements. Mean Bazett QTc was higher compared to the other 3 formulae: 412 ± 20 vs. 400 ± 16 msec. Using Bazett formula, 18/188 (9.6%) and 5/188 (2.7%) subjects showed at least one measurement with ΔQTc ≥60 msec and QTc ≥500 msec, respectively. Of the former, 5/18 (27.8%) showed QTc ≥25% prolongation. In multivariate analysis, QTc ≥500 msec was significantly associated with number of measurements (HR: 5.01, 95%CI: 1.21-20.78, p = .026) with no effect of other known confounders. Lower rates were demonstrated with the other three formulae.
CONCLUSION
In clinical practice, significant prolonged QTc may be attributed to within-individual variability, particularly when adjusting the QT interval with Bazett correction. This should be taken into consideration when decisions on changing current drug regimens are to be made.

Identifiants

pubmed: 31498534
doi: 10.1111/anec.12699
pmc: PMC7358820
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e12699

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Int J Biostat. 2016 Nov 1;12(2):
pubmed: 27838682
Eur J Clin Pharmacol. 2017 Sep;73(9):1181-1185
pubmed: 28624887
Heart Rhythm. 2017 Jul;14(7):974-978
pubmed: 28323171
BMC Pharmacol Toxicol. 2016 Mar 10;17:12
pubmed: 26960809
Heart Rhythm. 2006 Sep;3(9):1003-7
pubmed: 16945790
Br J Clin Pharmacol. 2013 Jul;76(1):48-57
pubmed: 23167578
Am J Physiol Heart Circ Physiol. 2002 Jun;282(6):H2356-63
pubmed: 12003846
J Am Heart Assoc. 2016 Jun 17;5(6):
pubmed: 27317349
Ann Noninvasive Electrocardiol. 2020 Mar;25(2):e12699
pubmed: 31498534
Br J Clin Pharmacol. 2009 Mar;67(3):347-54
pubmed: 19523015
Cardiology. 2011;120(2):103-10
pubmed: 22156660
J Am Coll Cardiol. 2015 Nov 17;66(20):2185-2188
pubmed: 26564595
QJM. 2007 Oct;100(10):609-15
pubmed: 17881416
Heart. 2002 Mar;87(3):220-8
pubmed: 11847158
Br J Clin Pharmacol. 2015 Oct;80(4):698-705
pubmed: 25966843
Eur Heart J. 2005 Oct;26(19):2007-12
pubmed: 15888497
J Cardiovasc Electrophysiol. 2001 Apr;12(4):411-20
pubmed: 11332559
J Cardiovasc Electrophysiol. 2006 Mar;17(3):333-6
pubmed: 16643414
J Pharmacol Methods. 1989 Nov;22(3):207-17
pubmed: 2586115

Auteurs

Itai Gueta (I)

The Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center, Tel Hashomer, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Robert Klempfner (R)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
The Olga and Lev Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel.

Noa Markovits (N)

The Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center, Tel Hashomer, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Hillel Halkin (H)

The Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center, Tel Hashomer, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Shlomo Segev (S)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
The Institute for Medical Screening, Sheba Medical Center, Tel Hashomer, Israel.

David Rott (D)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
The Olga and Lev Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel.

Yael Peled (Y)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
The Olga and Lev Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel.

Ronen Loebstein (R)

The Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center, Tel Hashomer, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH